{
    "nctId": "NCT00399802",
    "briefTitle": "A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)",
    "officialTitle": "A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women With Breast Cancer and Established Bone Metastases (MBD)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Bone Disease",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 43,
    "primaryOutcomeMeasure": "Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has histologically or cytologically-confirmed breast cancer\n* Patient has documented skeletal metastases\n\nExclusion Criteria:\n\n* Patient is undergoing current oral bisphosphonate therapy, or has a history of oral bisphosphonate use within 6 months of entry into study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}